Porous poly(cyclohexane-1,4-diyl acetone dimethylene ketal) (PCADK)/poly(d,l-lactide-co-glycolide) (PLGA) mixed-matrix porous microspheres loaded with doxorubicin (Dox) were successfully prepared, and PCADK/PLGA 2/8 was selected as the optimal mixed-matrix proportion. The optimal porous microspheres were characterized by a uniform spherical morphology, an obvious porous surface, an adaptive aerodynamic diameter (2.48 μm), good lung deposition and excellent encapsulation efficiency (77.22 %). The total release of Dox from PCADK/PLGA microspheres was 64.66 %, which was greater than the 46.31 % from the PLGA microsphere group, resulting in the porous PCADK/PLGA microspheres showing a stronger antiproliferative effect than the porous PLGA microspheres. The antiproliferative mechanism was examined through flow cytometry analysis and protein expression level detection, exhibiting enhanced tumor-related protein regulation, improved cell apoptosis induction and increased cycle arrest. Finally, a BALB/c mouse lung cancer model was established to evaluate the in vivo anticancer efficacy, and the PCADK/PLGA microspheres showed significantly stronger anticancer effects than the PLGA microspheres. We envision that employment of this mixed polymer material as a microsphere matrix could be a promising strategy for lung cancer therapy via pulmonary administration.

成功制备了载有阿霉素（Dox）的多孔聚（环己烷-1,4-二乙丙酮二亚甲基缩酮）（PCADK）/聚（d，l-丙交酯-乙交酯乙交酯）（PLGA）混合基质多孔微球，选择/ PLGA 2/8作为最佳混合矩阵比例。最佳的多孔微球具有均匀的球形形态，明显的多孔表面，适应性的空气动力学直径（2.48μm），良好的肺部沉积和出色的包封效率（77.22％）。PCADK / PLGA微球中Dox的总释放为64.66％，大于PLGA微球组的46.31％，导致多孔PCADK / PLGA微球显示出比多孔PLGA微球更强的抗增殖作用。通过流式细胞术分析和蛋白质表达水平检测检查了抗增殖机制，表现出增强的肿瘤相关蛋白质调节，改善的细胞凋亡诱导和增加的周期停滞。最后，建立了BALB / c小鼠肺癌模型以评估体内抗癌效果，并且PCADK / PLGA微球显示出比PLGA微球明显更强的抗癌作用。我们设想使用这种混合聚合物材料作为微球基质可能是通过肺部给药进行肺癌治疗的有前途的策略。PCADK / PLGA微球的抗癌作用比PLGA微球强得多。我们设想使用这种混合聚合物材料作为微球基质可能是通过肺部给药进行肺癌治疗的有前途的策略。PCADK / PLGA微球的抗癌作用比PLGA微球强得多。我们设想使用这种混合聚合物材料作为微球基质可能是通过肺部给药进行肺癌治疗的有前途的策略。